Developer docs
API playgroundTry for free, no card

Search company profiles

AdjuCor

Full company profile

uuid0002fde

Namestring
AdjuCor
Legal namestring
AdjuCor GmbH
Websiteurl
adjucor.com
Company typeenum
Private
Founded yearint
2012
Descriptiontext

AdjuCor GmbH is a Munich-based, privately held medical device company founded in 2012 by cardiothoracic surgeon Prof. Stephen Wildhirt. The company is developing a single platform product, reBEAT, a biventricular mechanical circulatory support device intended for patients with advanced heart failure awaiting heart transplantation or in need of temporary circulatory support. reBEAT works by applying synchronized pulsatile force from the epicardium (outside the heart) without making any contact with blood, and is implanted minimally invasively on the beating heart without sutures. The product is positioned as a differentiated alternative to existing blood-contacting ventricular assist devices (VADs), with claims of reduced stroke and bleeding risk, shorter procedure times, and faster patient mobilization.

The underlying technology platform combines a patented extravascular architecture with patient-specific design; AdjuCor is also developing 3D-printable biomimetic polymers through the BMBF-funded PolyKARD consortium (Fraunhofer IAP, NMI, pro3dure medical, Young Optics) to enable customized implants. The company has built a clinical evidence base including a 60-day chronic animal survival study and the world's first-in-human trial of an extravascular biventricular cardiac assist device, completed in 2025 with results published in JACC: Basic to Translational Science. Strategic clinical partners include Hannover Medical School (first-in-human site, with Prof. Arjang Ruhparwar as clinical advisor) and Royal Brompton and Harefield Hospitals (with Prof. Ulrich Stock as clinical advisor).

The business model is pre-commercial: reBEAT is currently used exclusively in clinical investigations and is not yet available for sale. Revenue mechanics will ultimately rest on direct hospital and cardiac surgery center sales of the implantable hardware, supplemented by potential licensing of the underlying non-blood-contacting technology. Capital structure to date reflects this stage: cumulative disclosed funding exceeds €44.5 million across private investors, the European Innovation Council (including a €29M Series B in June 2021 and a €2.5M EIC Accelerator grant in June 2022), and German federal and Bavarian government entities. GTM motion is enterprise field sales into cardiac surgery centers, layered with conference-led KOL engagement (ISHLT, AATS). The company employs 40+ staff across development, manufacturing, clinical, and support functions and is preparing for a US clinical study as the next major milestone.

Short descriptiontext

AdjuCor GmbH is a Munich-based medical device company developing reBEAT, a biventricular, epicardial mechanical circulatory support device that avoids blood contact. It is intended for advanced heart failure patients awaiting heart transplantation, currently in clinical investigation and not yet commercially available.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersMunich, Germany
HQ citystring
Munich
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cardiac assist devices, mechanical circulatory support, ventricular assist technology, heart failure treatment, extravascular heart pump
Industry2 codes
PRIMARYHLAHAFAG
Mechanical Circulatory Support (VAD, IABP, ECMO)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHLAHAFAL
Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
NAICS code1 code
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code1 code
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Cardiac Assist Devices
No data
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Medical Device Sales
TypeHardware Sales
Description

Sale of the reBEAT cardiac support device to hospitals and cardiac surgery centers. Currently exclusively used in clinical investigations and not yet available for sale.

adjucor.com
2Technology Licensing
TypeLicensing Royalties
Description

Potential licensing of proprietary technology and patents related to non-blood-contacting cardiac support systems.

adjucor.com
3Grant Funding
TypeManaged Services
Description

Non-dilutive funding from European Union, German federal government (BMBF), and Bavarian provincial government for research and development activities.

adjucor.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Supply Chain
Pricing details1 tier
1Device pricing not publicly disclosed - pre-commercial stage
ModelOtherBilling cadenceMulti-year contract
Notes

Currently in clinical investigation phase; not yet available for commercial sale. Pricing will be determined upon regulatory approval and market launch.

adjucor.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1reBEAT
Description

A biventricular cardiac support device - a minimally invasive, epicardial mechanical circulatory support technology designed to assist one or both ventricles of the failing heart without blood contact.

adjucor.com
Core offering1 text field

AdjuCor develops and is commercializing the reBEAT system, a biventricular mechanical circulatory support device that is implanted minimally invasively on the beating heart around the epicardium. The device applies synchronized pulsatile force from outside the heart to support pump function without any blood contact, targeting patients with advanced heart failure awaiting transplantation. The product is currently in clinical investigation phase and not yet available for commercial sale.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Reduced stroke and bleeding risk compared to blood-contacting devices
+3 more records
Product overview1 text field

AdjuCor operates as a single-product company focused exclusively on the reBEAT system — a biventricular, minimally invasive, epicardial cardiac support device that provides mechanical circulatory support without blood contact. The company's entire portfolio centers on this one technology platform, which works by applying synchronized pulsatile force from the epicardium to support one or both ventricles of the failing heart. The product is currently in clinical investigation phase and not yet available for commercial sale.

Product and service1 record
1reBEAT Cardiac Support System
CategoryCardiac Assist Devices / Mechanical Circulatory Support
Description

A biventricular mechanical circulatory support device that is implanted minimally invasively on the beating heart around the epicardium. The device applies synchronized pulsatile force from outside the heart to assist pump function without any blood contact. It is designed for patients with advanced heart failure awaiting transplantation, supporting one or both heart chambers with patient-specific adjustable energy transfer.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership10 partners
1Fraunhofer Institute for Applied Polymer Research IAP
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-02-04
Description

PolyKARD project partner developing 3D printable biomimetic polymers that mimic properties of the pericardium for customized implants.

adjucor.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-02-04
Description

PolyKARD project partner testing polymers for in vitro cytotoxicity and processing using 3D printing methods and electrospinning.

3pro3dure medical GmbH
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2020-02-04
Description

PolyKARD project partner establishing upscaling process of photopolymers and resin synthesis under GMP guidelines.

adjucor.com
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2020-02-04
Description

PolyKARD project partner developing 3D printing system for production of class III medical products with complete traceability.

5VDI Verein Deutscher Ingenieure e.V.
Strategic tierMinorTypeImplementation/ SI/ Consulting PartnerAnnounced on2020-02-04
Description

Project management agency for PolyKARD project on behalf of BMBF.

adjucor.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Academic partner providing research collaboration and clinical expertise in cardiac surgery and heart failure treatment.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Academic partner for cardiac research and development collaboration.

8Hochschule München (HSM)
Strategic tierMinorTypeStrategic or Co-development Partner
Description

University partner for applied research in medical device development.

adjucor.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Clinical partner for first-in-human trial of reBEAT. Prof. Arjang Ruhparwar serves on Clinical Advisory Board.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Clinical advisor Prof. Ulrich Stock provides consultation on cardiac surgery and heart failure treatment using reBEAT.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

French medtech developing a novel, fully implantable cardiac assist device (ICOMS) targeting advanced heart failure. Closest comparable to AdjuCor's reBEAT as another next-generation, minimally invasive cardiac assist platform pursuing a differentiated non-LVAD architecture.

TypeDirect peer
Description

French medtech developing a next-generation LVAD based on a biomimetic wave-membrane pump producing pulsatile flow. Directly comparable to AdjuCor as a developer of novel mechanical circulatory support technology targeting improved physiologic blood flow versus continuous-flow LVADs.

3Abbott
TypeBroad incumbent
Description

Global medtech leader and maker of HeartMate 3, the dominant durable LVAD in clinical use. Direct incumbent in mechanical circulatory support; AdjuCor's reBEAT is positioned as a differentiated alternative to Abbott's blood-contacting LVAD platform.

TypeBroad incumbent
Description

Global medtech incumbent that previously marketed the HVAD system (discontinued in 2021). Broad incumbent in cardiac surgery and heart failure with deep clinical relationships; a credible strategic acquirer of novel MCS technologies like AdjuCor's.

TypeEmerging player
Description

UK-based early-stage company developing miniVAD, a fully implantable, miniature ventricular assist device. Comparable emerging player pursuing miniaturized, less-invasive mechanical circulatory support targeting the same advanced heart failure population.

6CARMAT
TypeEmerging player
Description

French medtech developing the Aeson total artificial heart for patients with end-stage biventricular heart failure. Comparable emerging player addressing advanced heart failure, though with a different modality (full heart replacement vs. assist).

7Evaheart
TypeEmerging player
Description

US/Japanese company developing the EVAHEART continuous-flow LVAD system. Comparable emerging player in mechanical circulatory support pursuing long-term destination therapy in the same advanced heart failure market.

TypeEmerging player
Description

Maker of the temporary Total Artificial Heart (TAH) used as a bridge to transplant. Comparable emerging player targeting the same advanced heart failure / transplant-bridge patient population, though using a different therapeutic modality.

TypeEmerging player
Description

US-based developer of Aortix, a percutaneous mechanical circulatory support device. Comparable emerging player pursuing novel, less-invasive circulatory support platforms relevant to the heart failure treatment paradigm.

TypeBroad incumbent
Description

Acquired by Johnson & Johnson MedTech, Abiomed is the leader in percutaneous ventricular assist devices (Impella) used in high-risk PCI and cardiogenic shock. Broad incumbent in mechanical circulatory support with overlapping customer base of cardiac surgeons and interventional cardiologists.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

AdjuCor

Cardiac Assist Devicesadjucor.com

AdjuCor GmbH is a Munich-based medical device company developing reBEAT, a biventricular, epicardial mechanical circulatory support device that avoids blood contact. It is intended for advanced heart failure patients awaiting heart transplantation, currently in clinical investigation and not yet commercially available.

What AdjuCor does

AdjuCor GmbH is a Munich-based, privately held medical device company founded in 2012 by cardiothoracic surgeon Prof. Stephen Wildhirt. The company is developing a single platform product, reBEAT, a biventricular mechanical circulatory support device intended for patients with advanced heart failure awaiting heart transplantation or in need of temporary circulatory support. reBEAT works by applying synchronized pulsatile force from the epicardium (outside the heart) without making any contact with blood, and is implanted minimally invasively on the beating heart without sutures. The product is positioned as a differentiated alternative to existing blood-contacting ventricular assist devices (VADs), with claims of reduced stroke and bleeding risk, shorter procedure times, and faster patient mobilization.

The underlying technology platform combines a patented extravascular architecture with patient-specific design; AdjuCor is also developing 3D-printable biomimetic polymers through the BMBF-funded PolyKARD consortium (Fraunhofer IAP, NMI, pro3dure medical, Young Optics) to enable customized implants. The company has built a clinical evidence base including a 60-day chronic animal survival study and the world's first-in-human trial of an extravascular biventricular cardiac assist device, completed in 2025 with results published in JACC: Basic to Translational Science. Strategic clinical partners include Hannover Medical School (first-in-human site, with Prof. Arjang Ruhparwar as clinical advisor) and Royal Brompton and Harefield Hospitals (with Prof. Ulrich Stock as clinical advisor).

The business model is pre-commercial: reBEAT is currently used exclusively in clinical investigations and is not yet available for sale. Revenue mechanics will ultimately rest on direct hospital and cardiac surgery center sales of the implantable hardware, supplemented by potential licensing of the underlying non-blood-contacting technology. Capital structure to date reflects this stage: cumulative disclosed funding exceeds €44.5 million across private investors, the European Innovation Council (including a €29M Series B in June 2021 and a €2.5M EIC Accelerator grant in June 2022), and German federal and Bavarian government entities. GTM motion is enterprise field sales into cardiac surgery centers, layered with conference-led KOL engagement (ISHLT, AATS). The company employs 40+ staff across development, manufacturing, clinical, and support functions and is preparing for a US clinical study as the next major milestone.

AdjuCor firmographics

Firmographics
Name
AdjuCor
Legal name
AdjuCor GmbH
Website
https://adjucor.com
Company type
Private
Founded year
2012
Operating status
Operating
Headcount range
11–50 employees
Short description
AdjuCor GmbH is a Munich-based medical device company developing reBEAT, a biventricular, epicardial mechanical circulatory support device that avoids blood contact. It is intended for advanced heart failure patients awaiting heart transplantation, currently in clinical investigation and not yet commercially available.
Ownership category
akta.pro rank

AdjuCor industry classification

Industry
Product category
Cardiac Assist Devices
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYHLAHAFAG
Mechanical Circulatory Support (VAD, IABP, ECMO)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHLAHAFAL
Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)

Keywords

  • Cardiac assist devices
  • Mechanical circulatory support
  • Ventricular assist technology
  • Heart failure treatment
  • Extravascular heart pump

Where AdjuCor is headquartered

Location

Headquarters

HQ city
Munich
HQ country
Germany
HQ region
Europe

Offices1 record

Markets served

AdjuCor business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Supply Chain

Revenue model

  1. Medical Device Sales: Sale of the reBEAT cardiac support device to hospitals and cardiac surgery centers. Currently exclusively used in clinical investigations and not yet available for sale.
  2. Technology Licensing: Potential licensing of proprietary technology and patents related to non-blood-contacting cardiac support systems.
  3. Grant Funding: Non-dilutive funding from European Union, German federal government (BMBF), and Bavarian provincial government for research and development activities.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractDevice pricing not publicly disclosed - pre-commercial stage

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

AdjuCor product offering

Product offering

Core offering

AdjuCor develops and is commercializing the reBEAT system, a biventricular mechanical circulatory support device that is implanted minimally invasively on the beating heart around the epicardium. The device applies synchronized pulsatile force from outside the heart to support pump function without any blood contact, targeting patients with advanced heart failure awaiting transplantation. The product is currently in clinical investigation phase and not yet available for commercial sale.

Product overview

AdjuCor operates as a single-product company focused exclusively on the reBEAT system — a biventricular, minimally invasive, epicardial cardiac support device that provides mechanical circulatory support without blood contact. The company's entire portfolio centers on this one technology platform, which works by applying synchronized pulsatile force from the epicardium to support one or both ventricles of the failing heart. The product is currently in clinical investigation phase and not yet available for commercial sale.

Differentiator

Problem solved

Functional benefit

Brands

  • reBEAT: A biventricular cardiac support device - a minimally invasive, epicardial mechanical circulatory support technology designed to assist one or both ventricles of the failing heart without blood contact.

Products and services

  • reBEAT Cardiac Support System A biventricular mechanical circulatory support device that is implanted minimally invasively on the beating heart around the epicardium. The device applies synchronized pulsatile force from outside the heart to assist pump function without any blood contact. It is designed for patients with advanced heart failure awaiting transplantation, supporting one or both heart chambers with patient-specific adjustable energy transfer.

Quantifiable outcome

  • Reduced stroke and bleeding risk compared to blood-contacting devices
  • +3 more outcomes

Companies that use AdjuCor

Customer profile

Named customers1 record

Segments2 records

Ideal customer profiles1 record

AdjuCor technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

AdjuCor partnerships and signals

Strategic signal

Partnerships

Ten partnerships are on record, tiered core and minor.

  • Fraunhofer Institute for Applied Polymer Research IAPcoreStrategic or Co-development Partner · 4 February 2020PolyKARD project partner developing 3D printable biomimetic polymers that mimic properties of the pericardium for customized implants.
  • NMI Natural and Medical Sciences InstitutecoreStrategic or Co-development Partner · 4 February 2020PolyKARD project partner testing polymers for in vitro cytotoxicity and processing using 3D printing methods and electrospinning.
  • pro3dure medical GmbHminorStrategic or Co-development Partner · 4 February 2020PolyKARD project partner establishing upscaling process of photopolymers and resin synthesis under GMP guidelines.
  • Young Optics Europe GmbHminorStrategic or Co-development Partner · 4 February 2020PolyKARD project partner developing 3D printing system for production of class III medical products with complete traceability.
  • VDI Verein Deutscher Ingenieure e.V.minorImplementation/ SI/ Consulting Partner · 4 February 2020Project management agency for PolyKARD project on behalf of BMBF.
  • Technical University of Munich (TUM)coreStrategic or Co-development PartnerAcademic partner providing research collaboration and clinical expertise in cardiac surgery and heart failure treatment.
  • Ludwig Maximilian University of Munich (LMU)coreStrategic or Co-development PartnerAcademic partner for cardiac research and development collaboration.
  • Hochschule München (HSM)minorStrategic or Co-development PartnerUniversity partner for applied research in medical device development.
  • Hannover Medical School (MHH)coreStrategic or Co-development PartnerClinical partner for first-in-human trial of reBEAT. Prof. Arjang Ruhparwar serves on Clinical Advisory Board.
  • Royal Brompton and Harefield HospitalscoreStrategic or Co-development PartnerClinical advisor Prof. Ulrich Stock provides consultation on cardiac surgery and heart failure treatment using reBEAT.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

AdjuCor competitors and assessment

Company assessment

Direct peers

  • FineHeart: French medtech developing a novel, fully implantable cardiac assist device (ICOMS) targeting advanced heart failure. Closest comparable to AdjuCor's reBEAT as another next-generation, minimally invasive cardiac assist platform pursuing a differentiated non-LVAD architecture.
  • CorWave: French medtech developing a next-generation LVAD based on a biomimetic wave-membrane pump producing pulsatile flow. Directly comparable to AdjuCor as a developer of novel mechanical circulatory support technology targeting improved physiologic blood flow versus continuous-flow LVADs.

Broad incumbents

  • Abbott: Global medtech leader and maker of HeartMate 3, the dominant durable LVAD in clinical use. Direct incumbent in mechanical circulatory support; AdjuCor's reBEAT is positioned as a differentiated alternative to Abbott's blood-contacting LVAD platform.
  • Medtronic: Global medtech incumbent that previously marketed the HVAD system (discontinued in 2021). Broad incumbent in cardiac surgery and heart failure with deep clinical relationships; a credible strategic acquirer of novel MCS technologies like AdjuCor's.
  • Abiomed (Johnson & Johnson MedTech): Acquired by Johnson & Johnson MedTech, Abiomed is the leader in percutaneous ventricular assist devices (Impella) used in high-risk PCI and cardiogenic shock. Broad incumbent in mechanical circulatory support with overlapping customer base of cardiac surgeons and interventional cardiologists.

Emerging players

  • Calon Cardio: UK-based early-stage company developing miniVAD, a fully implantable, miniature ventricular assist device. Comparable emerging player pursuing miniaturized, less-invasive mechanical circulatory support targeting the same advanced heart failure population.
  • CARMAT: French medtech developing the Aeson total artificial heart for patients with end-stage biventricular heart failure. Comparable emerging player addressing advanced heart failure, though with a different modality (full heart replacement vs. assist).
  • Evaheart: US/Japanese company developing the EVAHEART continuous-flow LVAD system. Comparable emerging player in mechanical circulatory support pursuing long-term destination therapy in the same advanced heart failure market.
  • SynCardia Systems: Maker of the temporary Total Artificial Heart (TAH) used as a bridge to transplant. Comparable emerging player targeting the same advanced heart failure / transplant-bridge patient population, though using a different therapeutic modality.
  • Procyrion: US-based developer of Aortix, a percutaneous mechanical circulatory support device. Comparable emerging player pursuing novel, less-invasive circulatory support platforms relevant to the heart failure treatment paradigm.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

AdjuCor financial estimates

Financial estimate

Revenue estimate

Valuation estimate

AdjuCor leadership team

Management profile

Number of profiles

Profiles4 records

AdjuCor funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

AdjuCor M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AdjuCor

What does AdjuCor do?

AdjuCor develops and is commercializing the reBEAT system, a biventricular mechanical circulatory support device that is implanted minimally invasively on the beating heart around the epicardium. The device applies synchronized pulsatile force from outside the heart to support pump function without any blood contact, targeting patients with advanced heart failure awaiting transplantation. The product is currently in clinical investigation phase and not yet available for commercial sale.

Is AdjuCor a public or private company?

AdjuCor is a private company. It is classified as venture growth investor backed and is currently operating.

When was AdjuCor founded?

AdjuCor was founded in 2012. It employs 11 to 50 people.

Where is AdjuCor based?

AdjuCor is headquartered in Munich, Germany, in the Europe region.

How does AdjuCor make money?

Three revenue lines are on record. Medical Device Sales are the primary driver. The others are technology Licensing and grant Funding.

Who are AdjuCor's main competitors?

Direct peers on record are FineHeart and CorWave. Broad incumbents are Abbott, Medtronic and Abiomed (Johnson & Johnson MedTech). Emerging players are Calon Cardio, CARMAT, Evaheart, SynCardia Systems and Procyrion.

Does AdjuCor have an API?

No public API is recorded for AdjuCor.

What industry is AdjuCor in?

AdjuCor's product category is Cardiac Assist Devices. Its primary akta.pro industry code is HLAHAFAG, Mechanical Circulatory Support (VAD, IABP, ECMO), with a secondary code of HLAHAFAL, Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation). Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals